Researchers at the US Food and Drug Administration (FDA) have discovered that a drug… asthma Which is widely prescribed by doctors, has been shown to be linked to severe mental health problems in some patients, according to the Reuters website.
Researchers have discovered that it is a drug asthmawhich is sold under the scientific name Montelukast, binds to several brain receptors that are important for psychological functioning.
Montelukast was a successful product after its launch in 1998, providing relief in pill form as an alternative to an inhaler, the company said with fewer side effects -legal that they were “like a sugar pill,” while the label was. says that any effect The drug’s effect on the brain was “minimal”, and generic versions of the drug are still prescribed to millions of adults and children each year.
But by 2019, thousands of reports of neuropsychiatric cases, including dozens of suicides, among patients who were prescribed the drug had accumulated on online forums and in the FDA’s tracking system.
After years of study, new scientific reports and research led the FDA in 2020 to add a “black box” warning to the label for montelukast, indicating serious mental health risks such as suicidal thoughts or actions.
The group also convened a group of experts around the same time to discuss why the drug could cause neurological and psychological side effects.
The results of the group’s work, which were preliminary and not previously reported or made public, were presented to a limited audience at a meeting of the American College of Toxicology in Austin, Texas, on Wednesday.
Jessica Oliphant, deputy director of the US National Center for Toxicology Research, said at the event that laboratory tests showed a “significant binding” of montelukast to multiple receptors found in the brain.
The FDA also confirmed the results of previous scientific research that showed that montelukast penetrates into the brain of mice.
Jessica Oliphant, deputy director of the US National Center for Toxicology Research, said more research is needed on how the drug accumulates in the nervous system. She said: “These data indicate that montelukast is found in the highest concentrations in areas of the brain known to be involved in psychological effects. “
2024-11-23 10:33:00
#FDA #warns #drug #widely #treat #asthma #affects #brain
Here are two PAA (Personal Asynchronous Activity) related questions for the provided interview transcript:
## Interview: Montelukast and Mental Health Concerns
**Host:** Welcome to World Today News. Today we’re discussing a disconcerting discovery regarding a common asthma medication, Montelukast. Joining us are Dr. Emily Carter, a pulmonologist specializing in asthma treatment, and Dr. David Lee, a neuropharmacologist who specializes in psychotropic drug effects. Welcome to both of you.
**Section 1: Unveiling the Surprise Link**
**Host:** Dr. Carter, montelukast has been a mainstay in asthma treatment for decades. What was your reaction to learning it might have a link to mental health issues?
**Dr. Carter:** I was genuinely surprised and concerned. We always prioritize patient well-being, and the potential for a drug we rely on to have such unintended consequences is unsettling.
**Host:** Dr. Lee, from a neurological standpoint, how significant is this finding that Montelukast binds to brain receptors associated with psychological function?
**Dr. Lee:** It’s deeply significant. This binding suggests a direct biological mechanism by which montelukast could impact mental health. The locations of these receptors in the brain, as highlighted by Dr. Oliphant’s research, are specifically linked to mood, sleep, and emotional regulation.
**Section 2: Understanding the Scope of the Issue**
**Host:** The FDA implemented a “black box” warning on montelukast in 2020. This usually indicates serious potential side effects. Dr. Carter, what steps should healthcare providers take in light of this new information?
**Dr. Carter:** Open communication with patients is crucial. We need to proactively discuss the potential risks and benefits of montelukast, especially for those with a history of mental health issues or who are experiencing any unusual psychological symptoms. We must also explore alternative treatment options.
**Host:** Dr. Lee, what kind of research needs to be conducted to further understand the scope of this issue?
**Dr. Lee:** Long-term studies are vital. We need to investigate the long-term impact of montelukast use on mental health, particularly in children, who are often prescribed this medication.
**Section 3: Patient Perspectives and Looking Ahead**
**Host:** This news is undoubtedly troubling for patients who rely on montelukast for asthma control. Dr. Carter, what advice would you give to patients who are currently taking this medication?
**Dr. Carter:** My advice would be to speak with your doctor immediately. Don’t stop taking medication without consulting a healthcare professional. We can work together to determine the best course of action based on your individual medical history and needs.
**Host:** This situation highlights the constant need for ongoing research and reevaluation of medications. Dr. Lee, what lessons can we learn from this?
**Dr. Lee:** This serves as a powerful reminder that our understanding of pharmaceuticals is constantly evolving. It emphasizes the importance of continued research, open communication between healthcare providers and patients, and a commitment to patient safety.
**Host:** Thank you both for shedding light on this important topic.
